Evaluating kidney function after nephrectomy using retinal imaging
Evaluation of the Degradation of Renal Function Post Nephrectomy According to Retinal Vascularisation Parameters "NEPHRIN"
This study is testing if looking at the eyes can help doctors see how kidney function changes in people who have had kidney surgery for cancer, to better manage their health afterward.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 42 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire Dijon Academic / other |
| Locations | 1 site (Dijon) |
| Trial ID | NCT04855123 on ClinicalTrials.gov |
What this trial studies
This study aims to assess the degradation of renal function in patients who have undergone nephrectomy for cancer by analyzing retinal vascularization parameters. It focuses on identifying early predictive markers for chronic kidney disease (CKD) progression, which is a significant risk following nephrectomy. By utilizing non-invasive retinal imaging techniques, the study seeks to improve preoperative assessments and guide decisions on the type of nephrectomy performed. The ultimate goal is to enhance patient management and outcomes post-surgery.
Who should consider this trial
Good fit: Ideal candidates are adults scheduled for total nephrectomy due to kidney cancer, with available kidney scan images.
Not a fit: Patients with a single functional kidney before nephrectomy or those with significant comorbidities like diabetes or metastatic cancer may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better prediction and management of chronic kidney disease in patients undergoing nephrectomy.
How similar studies have performed: While the approach of using retinal imaging for predicting kidney function is innovative, similar studies have shown promise in correlating microcirculation with kidney disease progression.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patient * Indication for total nephrectomy for kidney cancer decided with a multidisciplinary oncology consultation * Kidney scan images available * Patient affiliated to French national health insurance * Patient who has given oral consent Exclusion Criteria: * Pregnant woman * Ophthalmologic history (macular vascular or degenerative diseases, epiretinal membranes, glaucoma) * Cannot sit still for 60 minutes * Metastatic cancer * Single functional kidney before nephrectomy * Estimated Glomerular Filtration Flow Rate (CKD-EPI formula) less than 60 mL/min/1.73m2 * Diabetes type 1 or type 2 * Proteinuria at inclusion (or in the 3 months prior to inclusion) on sample with a protein/creatinuria ratio greater than 1g/g or over 24 hours greater than 1g/day * HIV, HCV or HBV positive serology * Patient subject to a measure of legal protection (guardianship, curatorship, etc.) SECONDARY EXCLUSION CRITERIA * Patient with increased pressure during the measurement of the intraocular pressure before dilation * Patient with histological abnormalities suggestive of nephropathy (excluding nephroangiosclerosis) or ischemic parenchymal sequelae of renal vein thrombosis in the pathological analysis of the nephrectomy sample
Where this trial is running
Dijon
- Chu Dijon Bourgogne — Dijon, France (Recruiting)
Study contacts
- Study coordinator: Mathieu LEGENDRE
- Email: mathieu.legendre@chu-dijon.fr
- Phone: 03.80.29.37.56
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.